Metronidazole may display anti-inflammatory features in periodontitis treatment: A scoping review.
Mol Oral Microbiol
; 39(4): 240-259, 2024 Aug.
Article
en En
| MEDLINE
| ID: mdl-38613247
ABSTRACT
AIM:
Metronidazole (MTZ) is an antimicrobial agent used to treat anaerobic infections. It has been hypothesized that MTZ may also have anti-inflammatory properties, but the evidence is limited and has not been previously reviewed. Thus, this scoping review aimed to answer the following question "What is the evidence supporting anti-inflammatory properties of metronidazole that are not mediated by its antimicrobial effects?"METHODS:
A scoping review was conducted according to the PRISMA-ScR statement. Five databases were searched up to January 2023 for studies evaluating the anti-inflammatory properties of MTZ used as monotherapy for treating infectious and inflammatory diseases.RESULTS:
A total of 719 records were identified, and 27 studies (21 in vivo and 6 in vitro) were included. The studies reported experimental evidence of MTZ anti-inflammatory effects on (1) innate immunity (barrier permeability, leukocyte adhesion, immune cell populations), (2) acquired immunity (lymphocyte proliferation, T-cell function, cytokine profile), and (3) wound healing/resolution of inflammation.CONCLUSION:
Taken together, this scoping review supported a potential anti-inflammatory effect of MTZ in periodontitis treatment. We recommend that future clinical studies should be conducted to evaluate specific MTZ anti-inflammatory pathways in the treatment of periodontitis.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Periodontitis
/
Metronidazol
/
Antiinflamatorios
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Mol Oral Microbiol
Año:
2024
Tipo del documento:
Article
País de afiliación:
Brasil